AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs: role for pro-angiogenic effects and alterations in type-2 diabetics by Mocharla, Pavani et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
AngiomiR-126 expression and secretion from circulating CD34+ and CD14+
PBMCs: role for pro-angiogenic effects and alterations in type-2 diabetics
Mocharla, Pavani; Briand, Sylvie; Giannotti, Giovanna; Dörries, Carola; Jakob, Philipp; Paneni,
Francesco; Lüscher, Thomas; Landmesser, Ulf
Abstract: Several peripheral blood mononuclear cell (PBMC)-derived cell populations can promote an-
giogenesis, and differences in CD34+ or CD14+ surface-expression have been used to separate PBMC-
subpopulations in this respect. AngiomiRs, microRNAs regulating angiogenesis, have been identified as
key regulators of angiogenic processes. The present study examines differential angiomiR-expression/secretion
from CD34+/CD14+; CD34+/CD14-; CD34-/CD14+; CD34-/CD14- PBMC-subsets and their relevance
for different pro-angiogenic properties. Notably, both circulating human CD34+/14+ and CD34+/14-
PBMC-subsets and their supernatants exerted more potent pro-angiogenic effects as compared to CD34-
PBMC-subsets. MiR-126 was identified as most differentially expressed angiomiR in CD34+ as compared
to CD34-PBMC-subsets, determined by miR-array and RT-PCR validation. Modulation of miR-126 by
anti-miR-126 or miR-mimic-126 treatment resulted in significant loss or increase of pro-angiogenic effects
of CD34+PBMCs. MiR-126 levels in supernatants of CD34+PBMC-subsets were substantially higher
as compared to CD34- PBMC-subsets. MiR-126 was secreted in microvesicles/exosomes, and inhibition
of their release impaired CD34+PBMCs pro-angiogenic effects. Notably, high-glucose treatment or dia-
betes reduced miR-126-levels of CD34+PBMCs, associated with impaired pro-angiogenic properties that
could be rescued by miR-mimic-126 treatment. The present findings provide a novel molecular mech-
anism underlying increased pro-angiogenic effects of CD34+PBMC-subpopulations, i.e. angiomiR-126
expression/secretion. Moreover, an alteration of angiomiR-126-expression in CD34+PBMC in diabetes
provides a new pathway causing impaired pro-angiogenic effects.
DOI: 10.1182/blood-2012-01-407106
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-69556
Originally published at:
Mocharla, Pavani; Briand, Sylvie; Giannotti, Giovanna; Dörries, Carola; Jakob, Philipp; Paneni, Francesco;
Lüscher, Thomas; Landmesser, Ulf (2013). AngiomiR-126 expression and secretion from circulating
CD34+ and CD14+ PBMCs: role for pro-angiogenic effects and alterations in type-2 diabetics. Blood,
121(1):226-236. DOI: 10.1182/blood-2012-01-407106
AngiomiR-126 expression and secretion from circulating CD34+ and CD14+ PBMCs - role 
for pro-angiogenic effects and alterations in type-2 diabetics 
 
Mocharla: microRNA126 in CD34+ cells and angiogenesis 
 
 
Pavani Mocharla1,2, Sylvie Briand1,2, Giovanna Giannotti1,3, Carola Dörries1,2, Philipp Jakob1,2, 
Francesco Paneni1,4, Thomas Lüscher1,2, Ulf Landmesser1,2 
 
1 Cardiovascular Centre, University Hospital Zurich and Cardiovascular Research,  
Institute of Physiology, University of Zurich, Switzerland 
2Center of Integrative Human Physiology, University of Zurich, Switzerland 
3 Cardiac and Thoracic Department, University Hospital of Cisanello, Pisa, Italy 
4 IRCCS Neuromed, Pozzilli, Italy. 
 
 
 
 
 
 
Correspondence to: 
 
Ulf Landmesser, MD, 
Cardiovascular Center, 
University Hospital Zurich, 
Raemistr 100 (C-Hof 111), 
8091 Zürich, Switzerland. 
Fax: 0041 44 255 4401 
Phone: 0041 44 255 9595 
E-mail: Ulf.Landmesser@usz.ch 
  2  
 
 
ABSTRACT 
Several peripheral blood mononuclear cell (PBMC)-derived cell populations can promote 
angiogenesis, and differences in CD34+ or CD14+ surface-expression have been used to 
separate PBMC-subpopulations in this respect. AngiomiRs, microRNAs regulating 
angiogenesis, have been identified as key regulators of angiogenic processes.  The present 
study examines differential angiomiR-expression/secretion from CD34+/CD14+; CD34+/CD14-; 
CD34-/CD14+; CD34-/CD14- PBMC-subsets and their relevance for different pro-angiogenic 
properties.  
Notably, both circulating human CD34+/14+ and CD34+/14- PBMC-subsets and their 
supernatants exerted more potent pro-angiogenic effects as compared to CD34-PBMC-subsets.  
MiR-126 was identified as most differentially expressed angiomiR in CD34+ as compared to 
CD34-PBMC-subsets, determined by miR-array and RT-PCR validation. Modulation of miR-126 
by anti-miR-126 or miR-mimic-126 treatment resulted in significant loss or increase of pro-
angiogenic effects of CD34+PBMCs.  MiR-126 levels in supernatants of CD34+PBMC-subsets 
were substantially higher as compared to CD34- PBMC-subsets. MiR-126 was secreted in 
microvesicles/exosomes, and inhibition of their release impaired CD34+PBMCs pro-angiogenic 
effects.  Notably, high-glucose treatment or diabetes reduced miR-126-levels of CD34+PBMCs, 
associated with impaired pro-angiogenic properties that could be rescued by miR-mimic-126 
treatment.   
The present findings provide a novel molecular mechanism underlying increased pro-angiogenic 
effects of CD34+PBMC-subpopulations, i.e. angiomiR-126 expression/secretion.  Moreover, an 
alteration of angiomiR-126-expression in CD34+PBMC in diabetes provides a new pathway 
causing impaired pro-angiogenic effects.  
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Introduction 
Several peripheral blood mononuclear cells (PBMC)-derived cell populations have been shown 
to promote angiogenesis and differences in both, CD34+ or CD14+ surface expression, have 
been used to separate functionally different PBMC sub-populations in this respect1-5. In 
particular, human CD34+ PBMC have been shown to promote angiogenesis in response to 
ischemia1,3,5, resulting largely from paracrine effects.  Administration of CD34+ PBMCs is also 
being evaluated as a potential treatment of ischemic heart disease and limb ischemia6,7.  
However, an impaired cardiovascular repair function of autologous patient-derived progenitor 
cells, in particular a reduced capacity to promote neo-vascularization, has been suggested in 
diabetes and ischemic heart disease8-12, that may limit the efficacy of cell-based therapies in 
these patients and the underlying mechanisms need to be fully elucidated.  
Moreover, PBMCs have been suggested as a source of both, early and late outgrowth 
“endothelial progenitor cells”2  and differences in CD14+ expression have been proposed to 
distinguish mononuclear cells representing a source of early or late outgrowth cells in this 
respect13.  The vast majority of early “endothelial progenitor cells” has been suggested to arise 
from CD14+ subpopulations of PBMCs, whereas late outgrowth “endothelial progenitor cells” 
with a potential for differentiation towards endothelial cells were reported to be derived from 
CD14- mononuclear cell fractions2,13.  
Importantly, several microRNAs (miRs) have recently been identified as critical regulators of 
vascular development and angiogenesis that have been termed angiomiRs14-17. Moreover 
detection of circulating miRs in serum/plasma as well as secretion of miRs or their release in 
apoptotic micro-particles has recently been reported, suggesting that miRs may also play a 
regulatory role outside of the cell and thereby impact on target cells18-22 
The present study was therefore designed to determine whether there is differential angiomiR 
expression of these different PBMC subsets, separated for CD34+ expression as well as CD14+ 
surface expression, i.e. CD34+CD14+ and CD34+14-  as well CD34-/14+ and CD34-14- PBMC 
subpopulations.  Furthermore, we aimed to examine the potential role of differential angiomiR 
expression for differences in the pro-angiogenic capacity.  In addition, the impact of high-
glucose or type-2 diabetes on angiomiR expression and its relevance for the altered pro-
angiogenic effects was examined. 
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Materials and Methods 
Cell Isolation: PBMCs from healthy male volunteers (age: 49±4 years) were isolated from buffy 
coats by density-gradient centrifugation, washed twice in phosphate-buffered saline (PBS) 
containing 2 mM EDTA and 0.5% serum albumin.  MNCs (~ 500x 106) were split, i.e. half of the 
PBMCs were incubated with anti-CD14 micro-beads (Miltenyi Biotec) for 30min., and separated 
through a column of a MACS separator (Miltenyi Biotec). The other half of PBMCs was 
incubated with Monocyte Isolation Kit II (Miltenyi Biotec) and isolated by negative selection 
according to the manufacturer’s instructions, to obtain untouched CD14- (200-250 x106 cells) 
and CD14+ (100-150 x106 cells)  fractions respectively. These fractions further underwent 2 
cycles of anti-CD34+ micro-bead selection (Miltenyi Biotec), resulting in CD34+CD14+, CD34+ 
CD14-, CD34-CD14+, CD34-CD14- fractions of MNCs.   
Anti-miR and miR-mimic-126 Transfection: CD34+ PBMCs were plated onto a 3cm dish over 
night and then harvested for electroporation. CD34+ cells (1x106) were transfected in 4mm 
cuvette with 25pmol of microRNA (scramble, anti-miR-126 (Exiqon) or miR-mimic-126 (Ambion) 
as indicated) in a total volume of 300µl. The conditions for electroporation were the following: 
250V, 125 µF. Cells were incubated for 48 hours at 37°C and 5% CO2.  
MicroRNA RT PCR array: Total RNA was extracted from the fresh isolated cells using the 
miRNeasy Mini Kit (Qiagen) according to the manufacturer’s recommendations. cDNA was 
generated from 1µg total RNA using the RT² microRNA First Strand Kit (SuperArray Bioscience) 
according to manufacturer's procedures. The Human Cell Differentiation & Development RT2 
microRNA PCR Array was carried out according to manufacturer's instructions. Real-time qRT–
PCR was performed using the RT² qPCR SYBR Green/ROX Master Mix (SuperArray 
Bioscience) with pre-validated primer sets. Thermocycling parameters on a MX3000P PCR 
cycler (Stratagene) were 95°C for 10 min, followed by 40 cycles of 95°C for 15s, 60°C for 40s 
and 72°C for 30s. Samples from each cell population were run at least in triplicate and 
expression levels on each array plate were normalised using SNORD44 as internal control, 
according to the formula  CtmiRCtSNORDNV  442  . 
Validation MicroRNA RT PCR: Total RNA was extracted using QIAzol Reagent (Qiagen) 
according to the manufacturer’s recommendations. 5ng of total RNA from each preparation was 
used for miRCURY LNA™ First-strand cDNA kit, in a final volume of 10µl, according to the 
manufacturer’s instruction (Exiqon). Real time PCR was performed in an MX3000P PCR cycler 
(Stratagene). All experiments were performed in at least quadruplicate using the miRCURY 
LNA™ microRNA PCR system (Exiqon). Each reaction (25μl) contained 0.4 μl cDNA, 10 pmol 
of each primer, 0.25μl of internal reference dye, and 12.5μl of SYBR Green master mix. The 
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amplification program consisted of 1 cycle at 95 °C for 10min., followed by 40 cycles with a 
denaturing phase at 95 °C for 20s and an annealing phase at 60 °C for 1min. Data were 
normalised to results obtained with primers specific for U6 or in case of supernatants using 
synthetic spike-in miRNA (Exiqon), according to the formula  CtmiRCtUNV  62 .  
Protein analysis: The cells were washed thrice with PBS and then fixed in 4% PFA. The cells 
were permeabilized with PBS/0.1% Triton X-100, and blocked in LI-COR buffer. The wells were 
then incubated with primary antibodies (1:200) in LI-COR blocking buffer (mouse anti-PI3KR2 
antibody, abcam) overnight at 4°C. Infrared anti-mouse IRDye800CW secondary antibody (1: 
200) and DRAQ5, highly cell permeable DNA-interactive agent, (1: 10,000) in PBS/0.5% 
Tween-20 were then added (50µl/well). The plates were imaged on Odyssey infrared scanner 
(LI-COR) using microplate2 settings with sensitivity of 4 in the 700 and 7 in the 800nm 
wavelength channels. Data were acquired by using Odyssey software (LI-COR), exported and 
analyzed in Excel (Microsoft).  
Preparation of conditioned medium for functional and miR-analysis: Freshly isolated cell 
fractions, transfected cells and HAECs were cultured in EGM-2, 10% FCS (Lonza) incubated at 
37°C and 5% CO2. After overnight / 48hours incubation, cells were washed with PBS, re-
suspended in EBM, 0.5%FCS (Lonza) and incubated for 12hours at 37°C and 5% CO2.  
In-vitro tube formation Assay: Matrigel assays were performed as described previously 23 with 
slight modifications.  Briefly, 2x103 cells of CD34+CD14+, CD34+ CD14-, CD34-CD14+, CD34-
CD14- PBMC fractions or transfected CD34+ cells  were seeded onto 96-well tissue culture 
plates coated with 30μL Matrigel (BD Biosciences) and co cultured with 8x103 human aortic 
endothelial cells (HAECs), resulting in a total cell density of 1x104 cells/well. Cells were 
examined after 5hours with an inverted microscope (Olympus) at 40× magnification for capillary-
like tube formation.  Photographs were taken in 5 fields and complete tube numbers were 
counted. 
Microvesicle (MV) and Exosome (Exo) Isolation from Cell Supernatants: The microvesicle 
and exosome fractions were isolated from cell supernatants as described previously24.  In brief, 
2x106 cells from one buffy coat were incubated in serum free media which was centrifuged at 
1000g for 10 min to remove cells. This supernatant was transferred to a new tube and 
centrifuged at 16Kg for 60 min, the pellet (microvesicles) was washed and re-suspended in 
phosphate-buffered saline (PBS, 137mM Sodium Chloride, 2.7mM Potassium Chloride, 10mM 
Sodium Phosphate dibasic, 2mM Potassium Phosphate monobasic at pH of 7.4). The 
supernatant of the 16Kg centrifugation was transferred to a new tube and further centrifuged at 
120Kg for 60min to pellet the exosomes.  The exosome depleted supernatant was then 
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centrifuged at 220Kg for 60min.  The final supernatant was concentrated using Amicon Ultra 
Centrifugal Filter Devices (Millipore) to a final volume of 0.5ml.  The pellets, microvesicles, 
exosomes, and 220K xg pellet were re-suspended in 0.5ml PBS, so that the total volume of 
medium contributing to each was identical. For blocking of microvesicle/exosome release from 
CD34+ cells, these cells were treated with GW-4869 (10µM) for 30min as previously described25 
in EGM-2 (10% FCS). 
Animals:  Animal experiments were approved by the local committee. Male NRMI nu/nu mice, 
aged 10-16 weeks were used for transplantation of human PBMC subpopulations. Mice were 
housed under specific pathogen-reduced conditions receiving autoclaved chow and water ad 
libitum. For in-vivo angiogenesis assays in diabetic mice; 5 week old C57BL/6 mice were used. 
Diabetes was induced with streptozotocin in as described previously26. After 3 weeks of 
diabetes the animals were used for the experiments. 
CD34+ Cell Isolation from Diabetic Patients: Written informed consent was obtained from all 
patients and healthy subjects, and the study protocol was approved by the local ethics 
committee. CD34+ PBMCs were also isolated from patients with type-2 diabetes and age-
matched healthy subjects to compare the microRNA expression levels (57±3 vs. 53±5 years; 
P=n.s.). 
 In-vivo Angiogenesis assays: 
PBMC sub-fractions: In-vivo matrigel plug assay was performed as described previously27 with 
the following modifications: 500µL of Matrigel Basement Membrane Matrix (BD Biosciences) 
containing 15 U of heparin (Sigma-Aldrich) was injected subcutaneously into 6- to 8-week-old 
female athymic nude mice along the abdominal midline. CD34+CD14+, CD34+ CD14-, CD34-
CD14+, CD34-CD14- fractions were re-suspended in 400µL of PBS and injected via tail vein.  
miR-mimic-126 administration: In C57BL/6 mice diabetic animals 100µL of Matrigel Basement 
Membrane Matrix (BD Biosciences) containing 15U of heparin (Sigma-Aldrich) was mixed with 
miR-mimic-126 and scrambled RNA (5, 15, 25 pmol each) and injected subcutaneously into the 
animals along the abdominal midline.  
Microvesicle and exosome administration: 
Increasing concentrations of the microvesicle and exosome fractions were mixed with 100µL of 
Matrigel Basement Membrane Matrix (BD Biosciences) containing 15U of heparin (Sigma-
Aldrich) and injected subcutaneously into the animals along the abdominal midline.   
Blood vessel quantification: After 4 days, blood vessel infiltration in Matrigel plugs was 
quantified by analysis of CD31-staining (BD pharmingen) with FITC-anti-rat antibody (AbD 
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Serotec). Sections were photographed (Nikon, Eclipse, TE300) at 100× magnification using 
NIS-Elements F3.0. For hemoglobin analysis, the Matrigel plug was removed after 4 days and 
homogenized in 100µL of de-ionized water. After centrifugation, the supernatant was used in 
the Drabkin assay (Sigma-Aldrich) to measure hemoglobin concentration. Stock solutions of 
hemoglobin are used to generate a standard curve. Results are expressed relative to plug 
weight. 
Statistical Analysis: Quantitative results are expressed as means ± SEM. Comparisons 
between groups were analysed using one-way ANOVA, followed by Bonferroni post-hoc test.  A 
value of P<0.05 was considered to be statistically significant. 
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Results 
Both CD34+CD14+ and CD34+CD14- PBMC subsets exhibit a substantially greater pro-
angiogenic capacity as compared to CD34-/CD14+ and CD34-/CD14- MNC subsets in-vitro 
and in-vivo   
Tube formation capacity was compared for two CD34+ PBMC subsets (CD34+CD14+ and 
CD34+CD14-) and two CD34- cell PBMC subsets (CD34-CD14+ and CD34-CD14-) isolated 
from circulating PBMCs.  Both CD34+ cell fractions had a substantially higher pro-angiogenic 
capacity as indicated by an increased tube formation capacity in HAEC-co-culture assay, as 
compared to CD34-CD14+ and CD34-CD14- PBMC fractions (Fig.1A,B). Since CD34+ PBMCs 
have been suggested to promote angiogenesis largely via paracrine mechanisms, conditioned 
medium from the CD34+ and CD34- PBMC fractions was assessed.  Supernatants from CD34+ 
PBMC fractions had a higher stimulatory capacity for tube formation as compared to CD34- 
PBMC-fraction supernatants.  No significant difference was observed between CD34+CD14+ 
and CD34+CD14- PBMC supernatants (Fig.1C). The analysis of the pro-angiogenic capacity in-
vivo, in line with the above results, suggested a higher pro-angiogenic stimulatory capacity of 
both CD34+ PBMC fractions as compared to CD34- PBMC fractions (Fig.1D).  Furthermore, we 
observed a more pronounced effect of CD34+ cells on angiogenesis in-vivo using the matrigel 
plugs with an increasing CD34+ cell number (Suppl. Fig. 3A).  
Increased angiomiR miR-126 expression in CD34+ as compared to CD34- PBMC subsets 
To investigate potential novel mechanisms explaining different pro-angiogenic effects in CD34+ 
and CD34- PBMC subpopulations, angiomiR expression patterns were assessed in the above 
cell populations.  Human Cell Differentiation & Development RT PCR array was performed 
using total RNA isolated from CD34+CD14+, CD34+ CD14-, CD34-CD14+, CD34-CD14- cell 
fractions. Within the 8 most expressed miRs of the microRNA array we identified the angiomiR 
miR-126 (Fig.2A i-viii). Moreover, the miR-126 was identified as the angiomiR that was most 
profoundly higher expressed in CD34+ as compared to CD34- MNC sub-fractions (Fig.2B i-viii). 
The expression profile of other angiomiRs detected in the array and validated are shown in 
Fig.3A,B. Of note, CD34-CD14+ PBMCs had also higher expression levels of potentially anti-
angiogenic miRs, such as miRs from the miR-17-92 cluster or miR-21 (Fig.3B).  
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Pro-angiogenic capacity of CD34+ PBMCs is dependent on miR-126 expression  
MiR-mimic-126 or anti-miR-126 treatment resulted in a markedly altered pro-angiogenic 
capacity of the CD34+, i.e. an enhanced tube formation was seen after miR-mimic-126 
transfection into CD34+ cells, whereas a decreased tube formation was observed in response 
to anti-miR-126 transfected CD34+ cells (Fig.4A,B). Similar results were observed when tube 
formation was examined in response to conditioned medium from CD34+ cells that were 
transfected with miR-mimic-126 or anti-miR-126, suggesting that the pro-angiogenic capacity of 
CD34+ cells is dependent on miR-126 and is largely mediated via paracrine factors (Fig.4C,D). 
CD34+ cells transfected with anti-miR-126 or miR-mimic-126 showed altered levels of miR-126, 
i.e. reduced or increased miR-126 levels, respectively (Fig.4E). 
MiR-126 is secreted from CD34+ cells largely in microvesicles/exosomes and stimulates 
angiogenesis 
MiR-126 levels were determined in supernatants from CD34+CD14+, CD34+CD14-, CD34-
CD14+, CD34-CD14- MNC populations, and observed significantly higher secretion of miR-126 
in supernatants of CD34+ cell populations. No significant difference was observed between the 
CD34+CD14+ and CD34+CD14- cell fractions (Fig.5A). Modulation of the expression of miR-
126 by anti-miR or miR-mimic-126 in CD34+ cells leads to a decrease or increase in the 
secretion of this angiomiR into supernatants, respectively (Fig.5B). MiR-126 was largely 
detected in microvesicles and to a lesser extent in exosomes (Fig.5C). Administration of 
microvesicles or exosomes derived from CD34+ cells to endothelial cells resulted in a 
stimulation of tube formation (Fig.4D).  Microvesicles or exosomes stimulated angiogenesis in 
the matrigel plug assay in-vivo and increasing concentrations of mirovesicles had a greater 
effect on in-vivo angiogenesis (Suppl. Fig.1A,B). We further examined the effects of 
microvesicles or exosomes derived from antimiR-126-transfected and miR-mimic-126 
transfected CD34+ cells on angiogenesis in the matrigel plug assay in-vivo. Microvesicles or 
exosomes from miR-126 deficient CD34+ cells had a substantially reduced effect on in-vivo 
angiogenesis (Suppl. Fig.2A,C), whereas microvesicels and exosomes derived from miR-mimic-
126 transfected cells had an enhanced effect on in-vivo angiogenesis (Suppl. Fig.2B,D).  
The transfer of secreted vesicles from CD34+ cells to the endothelial cells was assessed by 
adding the supernatants from PKH67 stained CD34+ cells. The vesicular fusion into endothelial 
cells resulted in acquisition of the color after overnight incubation. The majority of endothelial 
cells acquired the color as assessed by flow-cytometry analysis (Fig.5E).  
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Blocking of the secretion of the vesicular particles by using GW4869 resulted in reduction of 
secreted miR-126 in the supernatant of the treated CD34+ cell and a subsequent increase of 
the miR in CD34+ cells (Fig.5F,G). GW4869 is an inhibitor of neutral sphingomyelinase 2 that 
regulates ceramide synthesis which is crucial for triggering the secretion of membrane 
vesicles25  Treatment of CD34+ cells with GW4869 lead to a loss of pro-angiogenic stimulation 
of the conditioned medium derived from these cells as compared to untreated CD34+ cells 
(Fig.5H). Moreover, we have also examined the effects of different doses of the miR-mimic-126 
or scrambled-miR on in-vivo angiogenesis. In these experiments, the higher doses of the miR-
mimic-126, but not of the scrambled-miR, had a more pronounced effect on in-vivo 
angiogenesis (Suppl. Fig.3B,C).   
High glucose treatment or diabetes leads to a loss of miR-126 expression and pro-
angiogenic effects of CD34+ PBMCs that can be restored by miR-mimic-126 transfection 
Exposure of CD34+ PBMCs to high-glucose substantially decreased their subsequent 
proangiogenic capacity as determined after washing of CD34+ PBMCs and subsequent co-
culture with HAECs, i.e. using an in-vitro tube formation assays (Fig.6A,B). This loss of function 
was likely due to an alteration of secreted factors since decreased tube formation in HAECs was 
observed after treatment with the conditioned medium from high-glucose treated CD34+ 
PBMCs (Fig.6C,D). Notably, expression of the pro-angiogenic miR-126 was down-regulated in 
high-glucose-treated CD34+ PBMCs as compared with buffer-treated cells in both, CD34+ 
CD34+ PBMCs and their supernatants (Fig.6E). Of-note, CD34+ PBMCs derived from patients 
with type-2 diabetes had a substantially decreased miR-126 expression as compared with age 
and sex-matched healthy subjects (Fig.6F).  
Furthermore, CD34+ PBMCs exposed to high-glucose were transfected with miR-mimic-126 or 
scrambled miR and their capacity to promote endothelial tube formation was subsequently 
assessed. Notably, miR-mimic-126 treated high-glucose exposed CD34+ PBMCs showed a 
marked improvement in the promotion of tube formation (Fig.7A,B).  
Direct exposure of endothelial cells to miR-mimic-126 stimulates angiogenesis in-vitro 
and in-vivo   
In addition, to determine whether miR-mimic-126 exposure of endothelial cells could directly 
impact angiogenesis, both in-vitro and in-vivo administration of miR-mimic-126 was examined.  
Notably, as described above we have observed that miR-126 is released from CD34+ cells.  
Moreover, CD34+ cell supernatants increased miR-126 levels in high-glucose-treated 
endothelial cells (Fig 7 C).  MiR-mimic-126 exposure, but not scrambled-miR administration to 
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high-glucose-treated endothelial cells significantly increased their miR-126 levels (data not 
shown). Notably, addition of the miR-mimic-126 directly to the medium of high-glucose exposed 
HAECs increased tube formation as compared to addition of scrambled-miR (Fig.7D) and down-
regulated PI3KR2, a known target of miR-126 in endothelial cells (Fig.7E). Moreover, addition of 
miR-mimic-126, but not scrambled miR directly to the matrigel plug implanted in streptozotocin-
induced diabetic animals enhanced tube formation and increased hemoglobin content (as a sign 
of increased new vessel formation) in the matrigel plug as compared with scrambled miR-
treated animals (Fig.7F,G). These findings suggest that direct exposure of miR-mimic-126 can 
promote these angiogenic processes. 
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Discussion 
In the present study we have observed a substantially higher expression of the angiomiR miR-
126 in human CD34+ as compared to CD34- PBMC subsets.  Notably, miR-126 was secreted 
by CD34+ PBMC subsets, largely in microvesicles and exosomes, and this secretion was 
altered by miR-mimic-126 or anti-miR-126 treatment.  Modulation of miR-126 expression levels 
by either miR-mimic-126 or anti-miR-126 revealed that miR-126 is critical for the pro-angiogenic 
capacity of CD34+ PBMCs.  In addition, we observed that reduced miR-126 expression is a 
novel mechanism leading to an impaired pro-angiogenic capacity in high-glucose-treated or 
diabetic patient-derived CD34+ PBMCs, which could be reversed by miR-mimic-126 treatment.   
Previous studies have suggested that at least 2 morphologically and functionally distinct 
“endothelial progenitor cell” populations can be derived after culture from circulating 
mononuclear cells according to duration of culture and the baseline CD14 phenotypic marker 
expression2,28. We have observed that the CD34+ fraction of cells showed a more potent pro-
angiogenic effect in-vitro and in-vivo, however, we did  not observe a significant difference 
between freshly isolated CD34+CD14+ and CD34+CD14- MNC-derived cell populations with 
respect to their pro-angiogenic capacity. Previous studies have demonstrated that monocytes 
can stimulate angiogenesis 2,4,28,29.  With the results of the present study one may speculate that 
the CD34+CD14+ MNC cell fraction may in particular contribute to such pro-angiogenic effects. 
We have observed that the CD34+ CD14+ MNC fraction resulted in a significant promotion of 
tube formation, very similar to that observed in the CD34+ CD14- MNC fraction.   
Notably, the present study for the first time demonstrates different angiomiR expression profiles 
in the PBMC sub-populations separated for their CD34+ and CD14+ surface expression. MiR-
126 was substantially increased in both, the CD34+CD14+ and CD34+CD14- PBMC 
populations and was critical for the increased pro-angiogenic capacity of the CD34+ PBMC 
population. Previously, miR-126 has been suggested to play a critical role in vascular 
development30,31. Moreover, following myocardial infarction miR-126 knockout mice showed 
impaired vascular growth in the infarct border zone30,31. A reduced expression of potentially anti-
angiogenic miRs in CD34+ cells as compared to CD34- cells, such as miR-15a or miR-20a 
levels observed in the present study, may also support an increased pro-angiogenic capacity of 
CD34+ cells. However, given the observation that anti-miR-126 treated CD34+ cells had lost the 
capacity to stimulate angiogenesis, these differentially expressed miRs are likely not sufficient to 
explain the functional difference observed between CD34+ and CD34- MNC cell subsets.  
Moreover, in the present study we have observed that the pro-angiogenic miR-126 is enriched 
in microvesicles and exosomes secreted by CD34+ progenitor cells and that these vesicles are 
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taken-up by endothelial cells. The increased miR-126 levels in vesicles correlated with an 
increased tube formation capacity. The presence of growth factors or other pro-angiogenic 
factors inside the vesicles 20, together with miR-126 likely mediates pro-angiogenic effects 
associated with these vesicles. The molecular content transported by CD34+ exosomes still 
remains to be fully characterised. Notably, exosomes with reduced miR-126 content did not 
stimulate the tube formation of endothelial cells; raising the possibility that miR-126 is a 
paracrine factor stimulating endothelial cell angiogenic activity. Zernecke et al have recently 
suggested that miR-126 is released from endothelial apoptotic micro-particles and acts in a 
paracrine way22. These micro-particles were incorporated by surrounding endothelial cells, and 
miR-126 transfer has been proposed to increase production of CXCL12 in endothelial cells, 
promoting homing of progenitor cells after vascular injury. 
In the present study we have observed that protein levels of phosphoinositol-3 kinase regulatory 
subunit 2 (PIK3R2), a known target of miR-126, are reduced in endothelial cells upon 
administration of miR-mimic-126, suggesting that the microRNA uptake regulates target 
expression in endothelial cells. PIK3R2 has been shown to inhibit pro-angiogenic signalling in 
endothelial cells by suppression of growth factor signalling via PI3 kinase pathways.30,31  
Diabetes has been observed to lead to an impaired function of early endothelial progenitor 
cells8,9,12. In the present study we suggest a novel link between loss of pro-angiogenic 
stimulation and reduced miR-126 levels in CD34+ cells in high-glucose treated cells. Plasma 
microRNA profiling in patients with type-2 diabetes has recently revealed reduced plasma levels 
of miR-126 in diabetic patients32. The present study newly demonstrates a reduced miR-126 
release from CD34+ PBMCs after high-glucose exposure and in diabetic patients that could 
contribute to reduced circulating miR-126 levels. 
The present observations do not exclude that other microRNAs beyond miR-126 may also 
regulate the angiogenic capacity of CD34+ cells as well that needs to be further explored in 
future studies.  For microRNA-126 we have shown that it is clearly promoting the pro-angiogenic 
capacity of CD34+ cells.  Others have reported that miR-126-knockouts had an impaired 
angiogenic response in the heart in the setting of myocardial ischemia and promote endothelial 
cell tube formation30.  At the same time, miR-126 has very recently been reported to suppress 
vascular growth in breast cancer metastasis by suppressing endothelial cell recruitment to 
metastatic cells via repression of other targets expressed in metastatic breast cancer cells33, 
suggesting that miR-126 does not promote tumor-associated angiogenesis. The effects of 
microRNA on angiogenesis may therefore substantially differ in diverse cell types and patho-
physiological settings. 
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Two other microRNAs that were found to be higher expressed in CD34+ cells as compared to 
CD34- mononuclear cells in the present study have very recently been suggested to be involved 
in the regulation of angiogenic processes in different endothelial cell types. We observed miR-
100 expression to be higher in CD34+ as compared to CD34- mononuclear cells. MiR-100 
expression in endothelial cells has been suggested to inhibit proliferation, tube formation, and 
sprouting activity and to act as an endogenous repressor of the serine/threonine protein kinase 
mammalian target of rapamycin34. This raises the possibility that this microRNA would rather 
limit the pro-angiogenic capacity of CD34+ mononuclear cells that needs, however, to be 
evaluated in future studies. MiR-10b was higher expressed in CD34+ as compared to CD34- 
mononuclear cells in the present study. MiR-10b has recently been suggested to regulate 
angiogenesis in human micro-vascular endothelial cells, where miR-10b over-expression 
promoted endothelial cell migration and tube formation35. These findings raise the possibility 
that this microRNA may also regulate pro-angiogenic effects in CD34+ mononuclear cells, that 
needs to be further evaluated in future studies.  However, miR-10b was substantially higher 
expressed in CD34+CD14+ as compared to CD34+CD14- mononuclear cells, that had a rather 
similar pro-angiogenic capacity in the present study, that would suggest that miR-10b is not a 
major regulator of pro-angiogenic effects of CD34+ mononuclear cells.  Vice versa, it is also 
possible that higher expression of potentially anti-angiogenic microRNA in CD34- mononuclear 
cells, such as from the miR-17-92 cluster or miR-21 as observed in the present study, may limit 
the pro-angiogenic capacity of CD34- mononuclear cells. 
In summary, our present findings demonstrate a differential angiomiR expression in CD34+ and 
CD34- PBMC subpopulations.  Increased angiomiR miR-126 expression in CD34+ PBMCs as 
compared to CD34- PBMCs was identified as a novel mechanism contributing to the increased 
capacity of these cells to promote angiogenic processes.  Moreover, down-regulation of miR-
126 in CD34+ PBMCs after high-glucose exposure or in diabetic patients represents a novel 
mechanism leading to an altered pro-angiogenic capacity in these conditions that can be 
rescued by miR-mimic-126 transfer.  
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Figure Legends 
Fig.1: CD34+CD14+ and CD34+CD14-+ PBMCs exhibit increased pro-angiogenic effects 
as compared to CD34-CD14+ and CD34-CD14- PBMCs.  
A: Quantification of tube formation by CD34+CD14+ and CD34+CD14- (white and black) 
as opposed to CD34-CD14+ and CD34-CD14- (grey), B: representative photographs of 
tube formation in high power field (n=8). C: conditioned medium of CD34+ fraction of 
PBMCs (white and black) promoting tube formation, which was not observed in the 
CD34- PBMC fractions (grey) (n=5-6) D: CD31 staining quantification by image j, in 
sections of in-vivo matrigel plug sections (n=4), ECs= endothelial cells. Data are mean ± 
SEM.  
Fig.2: MicroRNA expression profiles in PBMCs separated for CD34+ and CD14+ surface 
expression.  
A: The 8 most abundant miRs detected using this array are shown. B: Moreover, 8 miRs 
were identified that were significantly higher expressed in CD34+ PBMCs as compared 
to CD34- PBMC subsets, of which miR-126 was the most abundant. CD34+CD14+ 
(white), CD34+CD14- (black), CD34-CD14+ and CD34-CD14- (grey). All miRNAs were 
normalized to SNORD6 and expressed as normalized values (NV). Data are mean ± 
SEM. 
Fig.3: Expression of pro-angiogenic angiomiR miR-126 is higher in CD34+ PBMC sub-
populations.  
A: Confirmation of microRNA-array results and expression of other potentially pro-
angiogenic angiomiR as determined by RT-PCR (n=6-8). B: Expression levels of other 
potentially anti-angiogenic miR in the different MNC subpopulations (n=6-8). All 
angiomiRs expression is normalized to U6 small nuclear RNA and expressed as 
normalized value (NV). U6 levels were not altered in the different MNC subpopulations 
(data not shown). Data are mean ± SEM.  
Fig.4:  Increased pro-angiogenic capacity of CD34+ PBMCs is critically dependent on 
miR-126 expression.  
A: Shows transfected CD34+ cells, with antimiR-126 (grey) and miR-mimic 126 (black), 
effect on tube formation stimulation respectively as compared with that of scrambled 
(white) transfected cells. B: Representative photographs of tube formation in high power 
field. (n=6-10) C: Supernatant of transfected CD34+ cells effect on pro-angiogenic 
stimulation of endothelial cells is shown D: Photographs of tube formation in high power 
field (n=4). E: Altered miR-126 expression levels upon transfection of CD34+ cells with 
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anti-miR-126 (grey) and miR-mimic-126 (black). (n=4-6)  MicroRNA expression is 
normalized to U6, small nuclear RNA and expressed as normalized value (NV).  Data 
are mean ± SEM. 
Fig.5: miR-126 is secreted by CD34+ PBMCs in microvesicular and exosomal fractions.  
A: Assessment of miR-126 levels in the supernatant of the different populations of blood 
MNCs: CD34+CD14+ (white), CD34+CD14- (black), CD34-CD14- cells (grey bars) (n=3-
5). B: miR-mimic-126 or antimiR-126 treatment leads to increased (black) or reduced 
(white) miR-126 levels in the supernatant respectively (n=4). C: Expression levels of 
miR-126 in various fractions of the supernatant (n=4). D: pro-angiogenic stimulation by 
microvesicles (white), exosomes (grey) and 220k pellet (black) (n= 4-6). E: 
Internalisation of vesiclesby endothelial cells, detected in FACS analysis by acquisition 
of PKH-67 stain (n=3). F-H: miR-126 expression levels in cells and supernatants of 
CD34+ cells treated with GW4869 and effect on tube formation (n=4). Data are mean ± 
SEM. 
Fig.6:  High glucose exposure/ diabetes leads to loss of pro-angiogenic effects and miR-
126 expression and release from CD34+ PBMCs.  
A: Effect of high glucose 25mM (black) treatment as compared with the normal glucose 
treated CD34+ cells (n=5-10). B: Representative photographs of tube formation in high 
power field. C: Supernatant of high glucose (black) treated cells as opposed to normal 
glucose (white) their effect on tube formation (n= 6-8). D: Photographs of tube formation 
in high power field. E: Assessment of miR-126 in high glucose treated healthy CD34+ 
cells compared to untreated CD34+ cells (n=4). F: Assessment of the miR-126 levels in 
patients with type-2 diabetes (black) CD34+ cells in comparison with healthy subjects 
(white) (n=3). HG- High glucose; NG- Normal glucose. Data are mean ± SEM. 
Fig.7:  Pro-angiogenic capacity of CD34+ cells and capillary formation is increased by 
increasing miR-126 levels in high glucose-treated CD34+ cells.  
A: High glucose treated CD34+ cells were transfected with scrambled (white) and miR-
mimic-126 (black) and the effects on endothelial cell tube formation are shown. B: 
Representative photograhs of tube formation in high power field. (n=4) C: MiR-126 levels 
in high-glucose-treated (HG) endothelial cells after treatment with healthy CD34+ cell 
supernatant. D: Effect of direct exposure of high-glucose-treated HAECs to 25pmol 
scrambled-miR (white) or miR-mimic-126 (black) on tube-formation is shown. n=5.  E: 
Expression levels of PI3KR2 in high-glucose-treated HAECs treated with 25pmol 
scrambled-miR (white) or miR-mimic-126 (black). (n=3-5) F: Capillaries in the plug were 
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assessed by staining for CD31 (green) and DAPI (blue) in in-vivo matrigel plug assay in 
diabetic mice (streptozotocin-induced) after administration of miR-mimic-126 or 
scrambled miR – a representative image is shown. G: Hemoglobin content was 
assessed in the subcutaneously implanted matrigel plugs of animals receiving 
scrambled or miR-mimic-126 (directly into plugs) (n= 4). Data are mean ± SEM. 
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Figure : 7
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